Affinity Asset Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Affinity Asset Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-147,500	Closed	-$4.73M	–	99
2024 Q3	$4.73M	Buy	147,500 +77,501	+111%	+$2.9M	0.64%	44
2024 Q2	$2.64M	Sell	69,999 -30,001	-30%	-$1.26M	0.3%	60
2024 Q1	$4.92M	Hold	100,000	–	–	0.61%	50
2023 Q4	$3.65M	Buy	100,000 +58,419	+140%	+$1.52M	0.67%	40
2023 Q3	$961K	Sell	41,581 -88,419	-68%	-$2.42M	0.27%	62
2023 Q2	$3.41M	Buy	+130,000	New	+$3.42M	1.19%	28
2022 Q4	–	Sell	-175,000	Closed	-$4.99M	–	80
2022 Q3	$4.99M	Buy	+175,000	New	+$5.02M	1.39%	20
2022 Q2	–	Sell	-247,000	Closed	-$13.9M	–	67
2022 Q1	$13.9M	Sell	247,000 -51,545	-17%	-$2.95M	2.23%	6
2021 Q4	$18.5M	Buy	298,545 +172,532	+137%	+$11.4M	6.72%	2
2021 Q3	$7.99M	Buy	126,013 +101,013	+404%	+$7.78M	2.02%	8
2021 Q2	$2.06M	Sell	25,000 -2,000	-7%	-$152K	0.74%	34
2021 Q1	$1.99M	Buy	+27,000	New	+$2.11M	0.67%	37

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Affinity Asset Advisors's SWTX Position: Q4 2024 in Review

Affinity Asset Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 147,500 shares — an estimated $4.73M sold.

Affinity Asset Advisors first reported a position in SWTX in Q1 2021 and held it in 12 quarters. The position peaked at $18.5M in Q4 2021. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

Affinity Asset Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
Affinity Asset Advisors sold 147,500 SpringWorks Therapeutics shares in Q4 2024, an estimated $4.73M.
Affinity Asset Advisors first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 12 quarters.
Affinity Asset Advisors's SpringWorks Therapeutics position peaked at $18.5M in Q4 2021.
216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.